Clinical Outcomes in High-Gradient, Classical Low-Flow, Low-Gradient, and Paradoxical Low-Flow, Low-Gradient Aortic Stenosis After Transcatheter Aortic Valve Implantation: A Report From the SwissTAVI Registry.
SwissTAVI
low‐flow, low‐gradient
outcomes in aortic stenosis
transcatheter aortic valve implantation
valvular heart disease
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
20 06 2023
20 06 2023
Historique:
medline:
21
6
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
Background In view of the rising global burden of severe symptomatic aortic stenosis, its early recognition and treatment is key. Although patients with classical low-flow, low-gradient (C-LFLG) aortic stenosis have higher rates of death after transcatheter aortic valve implantation (TAVI) when compared with patients with high-gradient (HG) aortic stenosis, there is conflicting evidence on the death rate in patients with severe paradoxical low-flow, low-gradient (P-LFLG) aortic stenosis. Therefore, we aimed to compare outcomes in real-world patients with severe HG, C-LFLG, and P-LFLG aortic stenosis undergoing TAVI. Methods and Results Clinical outcomes up to 5 years were addressed in the 3 groups of patients enrolled in the prospective, national, multicenter SwissTAVI registry. A total of 8914 patients undergoing TAVI at 15 heart valve centers in Switzerland were analyzed for the purpose of this study. We observed a significant difference in time to death at 1 year after TAVI, with the lowest observed in HG (8.8%) aortic stenosis, followed by P-LFLG (11.5%; hazard ratio [HR], 1.35 [95% CI, 1.16-1.56];
Identifiants
pubmed: 37301760
doi: 10.1161/JAHA.123.029489
pmc: PMC10356021
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e029489Références
J Am Coll Cardiol. 2018 Mar 27;71(12):1297-1308
pubmed: 29566812
Circulation. 2013 Aug 6;128(6):622-31
pubmed: 23812184
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
J Cardiovasc Med (Hagerstown). 2021 Jun 1;22(6):486-491
pubmed: 33229861
J Am Heart Assoc. 2018 Apr 13;7(8):
pubmed: 29654191
EuroIntervention. 2014 Dec;10(8):982-9
pubmed: 24694729
EuroIntervention. 2014 Nov;10(7):850-9
pubmed: 25415152
Am J Cardiol. 2019 Aug 1;124(3):423-429
pubmed: 31138402
J Am Coll Cardiol. 2015 Jan 6;65(1):55-66
pubmed: 25572511
Circulation. 2007 Jun 5;115(22):2856-64
pubmed: 17533183
J Am Coll Cardiol. 2015 Dec 15;66(23):2594-2603
pubmed: 26670058
Circulation. 2020 May 26;141(21):1670-1680
pubmed: 32223336
J Am Coll Cardiol. 2012 Oct 2;60(14):1259-67
pubmed: 22657269
EuroIntervention. 2014 Nov;10(7):842-9
pubmed: 25415151
J Cardiol. 2015 May;65(5):360-8
pubmed: 25687368
J Am Coll Cardiol. 2013 Aug 27;62(9):782-8
pubmed: 23770162
JACC Cardiovasc Interv. 2019 Apr 22;12(8):752-763
pubmed: 31000012
Circ Cardiovasc Interv. 2021 Mar;14(3):e010042
pubmed: 33685217
Circulation. 2013 Jun 11;127(23):2316-26
pubmed: 23661722
Eur Heart J. 2011 Jan;32(2):205-17
pubmed: 21216739
J Am Coll Cardiol. 2012 Nov 6;60(19):1845-53
pubmed: 23062546
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):242-251
pubmed: 30304513
J Am Coll Cardiol. 2022 Aug 16;80(7):666-676
pubmed: 35953133
Eur Heart J. 2013 Nov;34(44):3437-50
pubmed: 24096324
J Am Coll Cardiol. 2015 Jan 6;65(1):67-71
pubmed: 25572512
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165